TrialEuropean journal of endocrinology2018

A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly.

Peter J Trainer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.